N-[(2S)-1-[2-[(2S,3S)-2-Hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethyl-1-oxobutyl]amino]-4-phenylbutyl]-2-[(4-phenylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamic acid methyl

BGC Id:	345882533365
CAS No:	229975-97-7
Synonyms:	zrivada ; 1-(4-biphenylyl)-4(s)-hydroxy-5(s)-2,5-bis{[n-(methoxycarbonyl-)-l-tert-leucinyl]amino}-6-phenyl-2-azahexane ; cgp 75355 ; atazanavir sulfate ; bms-232632-05 ; aids060276 ; methyl((5s,10s,11s,14s)-11-benzyl-5-(tert-butyl)-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-(4-(pyridin-2-yl)benzyl)-2-oxa-4,7,8,12-tetraazahexadecan-14-yl)carbamatesulfate ; aids-060276 ; atazanavir sulfate (bms-232632-05) ; atazanavir sulphate
Molecular Formula:	C38H52N6O7 . H2SO4
Molecular Weight:	802.93
EINECS:

What other providers are available for CAS 229975-97-7?

Identify

Synonyms:

zrivada ; 1-(4-biphenylyl)-4(s)-hydroxy-5(s)-2,5-bis{[n-(methoxycarbonyl-)-l-tert-leucinyl]amino}-6-phenyl-2-azahexane ; cgp 75355 ; atazanavir sulfate ; bms-232632-05 ; aids060276 ; methyl((5s,10s,11s,14s)-11-benzyl-5-(tert-butyl)-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-(4-(pyridin-2-yl)benzyl)-2-oxa-4,7,8,12-tetraazahexadecan-14-yl)carbamatesulfate ; aids-060276 ; atazanavir sulfate (bms-232632-05) ; atazanavir sulphate

CAS:

229975-97-7

EINECS:

Molecular Formula:

C38H52N6O7 . H2SO4

MDL:

MFCD08067748

Properties

Molecular Weight:

802.93 g·mol−1

What other providers are available for CAS 229975-97-7?

In addition to the providers presented here for N-[(2S)-1-[2-[(2S,3S)-2-Hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethyl-1-oxobutyl]amino]-4-phenylbutyl]-2-[(4-phenylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamic acid methyl with the CAS number 229975-97-7, there are other 49 providers with slightly different product names available for this CAS number.

Atazanavir sulfate

Methyl ((5S,10S,11S,14S)-11-benzyl-5-(tert-butyl)-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-(4-(pyridin-2-yl)benzyl)-2-oxa-4,7,8,12-tetraazahexadecan-14-yl)carbamate sulfate

BLD Pharmatech Ltd +1 additional providers that we know from the past